Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2020

View Archived Issues

Early clinical data reported for [177Lu]rhPSMA-7.3 in mCRPC

Merck & Co. advances MK-4830 into phase II trial in NSCLC

AGTC presents positive data from ongoing phase I/II clinical program in XLRP

Pfizer announces positive data from phase III JADE REGIMEN study of abrocitinib

Kuling Therapeutics patents RORC antagonists

Shanghai Institute of Materia Medica discloses NR1H4 agonists

Massachusetts Institute of Technology synthesizes compounds for cancer

Alectrona presents new quaternary amine compounds for infections

RECCE-327 demonstrates encouraging preliminary antiviral activity against SARS-CoV-2

Y-Biologics discloses IL-17A- and TNFalpha-targeting antibodies

Metabolic pathway-based TNBC subtyping reveals potential new targets

EZH2 as novel therapeutic target for chronic kidney disease

Data presented for NKTR-255 in patients with relapsed/refractory hematologic malignancies

Experimental aorta transplantation ameliorates uremic vascular calcification in rats

New immune checkpoint antibody AbGn-168H displays promising efficacy and is well tolerated

KAHR initiates first-in-human trial of DSP-107 in solid tumors

China IND approval for Apollomics' multikinase inhibitor APL-102

Sorrento files IND for phase I study of intranasal COVI-DROPS

New phase I study evaluates EDG-5506 for Becker muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld Science
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...